RxDoctor Payments Data

Darrell New, APRN

Family · Murray, KYNPI 1235505827

Payments from drug & device makers

$2,567in general payments, 2019–2025

Across 156 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$524
  • AstraZeneca$239
  • Novo Nordisk$230
  • Amgen$215
  • Boehringer Ingelheim$181
  • Otsuka America Pharmaceutical, Inc.$178
  • plus $1000 from 24 others

What the payments were for

  • Food & beverage$2,567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,567 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$56,161
Medicare patients
380
Services billed
2,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$24,804
FarxigaDapagliflozin Propanediol24$20,547
LybalviOlanzapine/Samidorphan Malate12$18,696
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$8,320
Esomeprazole Magnesium16$1,623
Ondansetron OdtOndansetron37$1,303
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort26$1,136
Albuterol Sulfate HfaAlbuterol Sulfate40$1,006
Olanzapine12$701
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen34$658
Ropinirole Hcl24$631
Gabapentin62$546
Levothyroxine Sodium56$524
Lisinopril118$491
Azithromycin151$475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$230$24,80419 claims
AstraZenecaFarxiga$239$20,54724 claims
Lilly USA, LLCOlanzapine$85$70112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Murray

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →